Sanofi India Ltd on Wednesday reported a 7.5% decline in profit for the third quarter ended September 30.

The drugmaker’s net profit came in at ₹76 crore, compared with ₹82 crore a year earlier.

Revenue from operations dropped 9.3% to ₹475.4 crore from ₹524 crore a year ago, the company said in an exchange filing.

Despite weaker sales, Sanofi India’s earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 12% to ₹134 crore, lifting its operating margin to 28% from 23% a year earlier, supported by cost efficiency measures and a favourable product mix.

The company, a unit of French drugmaker Sanofi SA, has been streamlining its portfolio in India to focus on core therapeutic areas such as diabetes and cardiovascular treatments.

Separately, the company’s board appr

See Full Page